Sector News

Novo Nordisk and NanoVation sign $600m deal in rare and cardiometabolic diseases

September 21, 2024
Life sciences

Novo Nordisk has signed a $600m deal with NanoVation to develop genetic medicines for rare and cardiometabolic diseases.

Novo has secured a licence to use NanoVation’s long-circulating lipid nanoparticle (lcLNP) technology for RNA delivery targeting cells outside the liver. Both companies will collaborate on two programmes to develop base-editing therapies for rare genetic diseases, with plans for up to five future targets for cardiometabolic and rare diseases.

Under the agreement, Novo is paying an undisclosed upfront fee. The multi-year deal could be worth up to $600m, with NanoVation set to receive research funding eligible for potential milestone payments, as well as tiered royalties on future product sales.

Novo has secured several deals in the past few years to maintain its dominant position in the cardiometabolic disease market. The Danish pharma company entered research collaborations with two US cell and gene therapy biotech startups in January, namely Omega Therapeutics and Cellarity.

In February 2024, Novo partnered with US-based biotech Neomorph in a collaboration and licensing agreement to discover and develop multiple molecular glue degraders for cardiometabolic disorders and rare diseases.

Novo has also shown its commitment to developing therapies for disorders with unmet needs such as metabolic dysfunction-associated steatohepatitis (MASH). The company’s collaboration with Cellarity involves the development of therapies for MASH, for which there are no treatments approved by the US Food and Drug Administration (FDA).

Novo’s Q1 2024 financial results highlighted that the company’s aspiration to expand the use of its blockbuster obesity products to cardiovascular indications has been successful. In March, its obesity drug Wegovy (semaglutide) was approved by the FDA for reducing the risk of cardiovascular diseases in obese or overweight adults. Semaglutide is also marketed as Ozempic in type 2 diabetes.

Wegovy generated $4.5bn in sales for Novo in 2023, as per the company’s financials. According to GlobalData analyst consensus forecasts, the drug is set to make $19.4bn in 2030.

GlobalData is the parent company of Pharmaceutical Technology.

In the announcement accompanying the deal, NanoVation’s co-founder Pieter Cullis said: “Genetic medicine is at a pivotal moment and this partnership marks a major milestone for NanoVation as an innovator in nucleic acid delivery. By combining NanoVation’s expertise in extrahepatic delivery with Novo Nordisk’s expertise in cardiometabolic and rare diseases we have the potential to create truly transformative therapies.”

by Jenna Philpott

Source: pharmaceutical-technology.com

comments closed

Related News

October 6, 2024

Meet Rosalie Harrison, Borderless Life Sciences Partner at CPHI Milan

Life sciences

“There’s no better place to meet our industry partners in person and get a first-hand feel for the state of the pharma industry than at CPHI,” says Borderless Partner Rosalie Harrison, who leads the firm’s life sciences practice.

October 6, 2024

Boehringer Ingelheim expands cancer research at Vienna Site

Life sciences

On Sep. 25, German biopharma company Boehringer Ingelheim opened its new 11,000 sqm Angelika Amon Research Building at its site in Vienna, Austria. According to Boehringer Ingelheim, the investment of around €60 million is further proof of the company’s commitment to cancer research.

October 6, 2024

Lilly announces new $4.5 Billion site

Life sciences

Eli Lilly and Company (Lilly) recently announced a $4.5 billion (€4.07 billion) investment to create the Lilly Medicine Foundry, a new center for advanced manufacturing and drug development. The facility will enable Lilly to research new methods of producing medicines and scale up manufacturing for clinical trials.